English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Clinical outcomes of chemotherapy for patients with advanced pancreatic adenocarcinoma in a real-world setting might differ from outcomes in randomized clinical trials (RCTs). Here we show in a single-institution cohort of 595 patients that median overall survival (OS) of patients who received gemcitabine alone ( n = 185; 6.6 months (95% CI; 5.5-7.7)) was the same as in pivotal RCTs. Gemcitabine/capecitabine ( n = 60; 10.6 months (95% CI; 7.8-13.3)) and gemcitabine/nab-paclitaxel ( n = 66; 9.8 months (95% CI; 7.9-11.8)) resulted in a longer median OS and fluorouracil/oxaliplatin/irinotecan ( n = 31, 9.9 months (95% CI; 8.1-11.7)) resulted in a shorter median OS than previously reported. Fluorouracil/oxaliplatin ( n = 35, 5.8 months (95% CI; 4.5-7)) and best supportive care ( n = 206, 1.8 months (95% CI; 1.5-2.1)) could not be benchmarked against any RCTs. The degree of protocol adherence explained differences between real-world outcomes and the respective RCTs, while exposure to second-line treatments did not.

Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort